2017

150.00 rub.
Buy article
2017/№S3

Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study

Nekrasov A. A.1, Timoshchenko E. S.2, Petelina I. S.2, Karpukhina E. V.1
1 – Nizhny Novgorod State Medical Academy, pl. Minina i Pozharskogo 10/1, Nizhny Novgorod 603005
2 – Municipal Clinical Hospital #5, Nesterova 34, Nizhny Novgorod 603005

Keywords: acetylsalicylic acid preparations, safety, copmliance, gastrointestinal disorders

DOI: 10.18087/cardio.2380

Aim. To study indexes of efficacy, safety and compliance for different ASA forms (Aspirin-Cardio, Cardiomagnyl, Thrombo ASS) used in stable IHD. Materials and methods. An open, cross-sectional study compared three groups of patients consisting of 200 patients each who had stable IHD and a high risk of gastrointestinal disorders and who received a long-term antiaggregant monotherapy with one of ASA drugs (group 1, Aspirin Cardio; group 2, Thrombo ASS; group 3, Cardiomagnyl). Efficacy, safety and compliance with the treatment were evaluated using standard tests and analogue scales; dyspepsia symptoms were evaluated using a special, additionally developed questionnaire. Results. The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1.4–1.6 times, р=0.001), requirement for proton pump inhibitors (р=0.002) and endoscopy during the ASA treatment the mean score of GI symptom questionnaire >3 predicted non-compliance or insufficient compliance with a diagnostic sensitivity of 58.9 % and specificity of 56.3 % (р=0.002), which makes this value a threshold for considering a modification of the treatment. Conclusion. Aspirin-Cardio is characterized by better safety in respect of GI symptoms and better compliance with the treatment during long-term prophylactic therapy. The proposed questionnaire for evaluation of GI symptoms can be used for specifying indications and modifying the treatment tactics.
  1. Шальнова С. А., Деев А. Д., Оганов Р. Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика. 2005;4 (1):4–9 [Shal`nova S. A., Deev A. D., Oganov R. G. Faktory`, vliyayushhie na smertnost` ot serdechno-sosudisty`x zabolevanij v rossijskoj populyaczii. Kardiovaskulyarnaya terapiya i profilaktika. 2005;4 (1):4–9].
  2. Лепахин В. К. Фармакология и лекарственная терапия. М.: Эксмо; 2009. 464 с [Lepaxin V. K. Farmakologiya i lekarstvennaya terapiya. M.: E`ksmo; 2009. 464 s].
  3. Косарев В. В., Бабанов С. А., Вербовой А. Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс; 2011. 477 с [Kosarev V. V., Babanov S. A., Verbovoj A. F. Spravochnik klinicheskogo farmakologa. Rostov-na-Donu: Feniks; 2011. 477 s].
  4. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71–86.
  5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2 (8607):349–60.
  6. Говорин А. В., Филёв А. П. Ацетилсалициловая кислота в профилактике атеротромбоза. Рациональная фармакотерапия в кардиологии. 2012;8 (2):237–41 [Govorin A. V., Filyov A. P. Aczetilsaliczilovaya kislota v profilaktike aterotromboza. Raczional`naya farmakoterapiya v kardiologii. 2012;8 (2):237–41].
  7. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991;114(10):835–9.
  8. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340 (8833):1421–5.
  9. Ежов М. В. Преимущества длительного применения клопидогрела у больных ишемической болезнью сердца. РМЖ. 2009;17(18):1140–3 [Ezhov M. V. Preimushhestva dlitel`nogo primeneniya klopidogrela u bol`ny`x ishemicheskoj bolezn`yu serdcza. RMZh. 2009;17 (18):1140–3].
  10. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37 (3):267–315. DOI:10.1093/eurheartj/ehv320.
  11. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35 (37):2541–619. DOI:10.1093/eurheartj/ehu278.
  12. Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003;52 (4):600–8.
  13. Яковенко Э. П., Иванов В. А., Яковенко А. В., Агафонова Н. А., Овчинникова Н. И., Алдиярова М. А. и др. Пептические язвы, патогенетические подходы к терапии. Фарматека. 2008; (13):62–8 [Yakovenko E`. P., Ivanov V. A., Yakovenko A. V., Agafonova N. A., Ovchinnikova N. I., Aldiyarova M. A. i dr. Pepticheskie yazvy`, patogeneticheskie podxody` k terapii. Farmateka. 2008; (13):62–8].
  14. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012;18 (18):2147–60. DOI:10.3748/wjg.v18.i18.2147.
  15. Feldman M, editor. Sleisenger & Fortran’s Gastrointestinal and Liver Disease: in 2 vol. 6th ed. Philadelphia: Saunders; 1998. 2046 p.
  16. Karateev AE, Nasonov EL, Yakhno NN, Ivashkin VT, Chichasova NV, Alekseeva LI et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology Journal. 2015; (1):4. DOI:10.14412/1996‑7012‑2015‑1‑4‑23.
  17. Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27 (7):1359–66. DOI:10.1185/03007995.2011.581274.
  18. Lanas A. A review of the gastrointestinal safety data - a gastroenterologist’s perspective. Rheumatology (Oxford). 2010;49 Suppl 2:ii3–10. DOI:10.1093/rheumatology/keq058.
  19. Багликов А. Н., Рафальский В. В. Значение приверженности пациентов к лечению при длительном приеме ацетилсалициловой кислоты у пациентов, перенесших острый коронарный синдром: результаты исследования. Кардиология. 2012;52 (9):22–8 [Baglikov A. N., Rafal`skij V. V. Znachenie priverzhennosti paczientov k lecheniyu pri dlitel`nom prieme aczetilsaliczilovoj kisloty` u paczientov, perenesshix ostry`j koronarny`j sindrom: rezul`taty` issledovaniya. Kardiologiya. 2012;52 (9):22–8].
  20. Rojas-Fernandez CH, Kephart GC, Sketris IS, Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 populationbased Nova Scotia Health Survey. Can J Cardiol. 1999;15 (3):291–6.
  21. Булахова Е. Ю., Кореннова О. Ю., Козырева В. А., Курочкина С. Д., Муротова С. А. Возможности снижения развития гастродуоденальных осложнений при длительном использовании препаратов ацетилсалициловой кислоты. Кардиоваскулярная терапия и профилактика. 2010;9(4):41–4 [Bulaxova E. Yu., Korennova O. Yu., Kozy`reva V. A., Kurochkina S. D., Murotova S. A. Vozmozhnosti snizheniya razvitiya gastroduodenal`ny`x oslozhnenij pri dlitel`nom ispol`zovanii preparatov aczetilsaliczilovoj kisloty`. Kardiovaskulyarnaya terapiya i profilaktika. 2010;9 (4):41–4].
  22. Каратеев А. Е. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013;51 (3):332–40 [Karateev A. E. Shest` nozhej v spinu ingibitoram protonnoj pompy`. Nauchno-prakticheskaya revmatologiya. 2013;51(3):332–40].
Nekrasov A. A., Timoshchenko E. S., Petelina I. S., Karpukhina E. V. Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study. Kardiologiia. 2017;57(S3):24–31

To access this material please log in or register

Register Authorize
Ru En